{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:51:07Z","timestamp":1790941867753,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":155,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.yrtph.2023.105438","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T13:52:29Z","timestamp":1687614749000},"page":"105438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Evaluation of non-clinical toxicity studies of COVID-19 vaccines"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1101-7671","authenticated-orcid":false,"given":"N.K.M.","family":"Schilder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Tiesjema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.T.","family":"Theunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Oude","family":"Rengerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"van der Laan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.yrtph.2023.105438_bib1","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/jat.3314","article-title":"Dose site reactions and related findings after vaccine administration in safety studies","volume":"36","author":"Baldrick","year":"2016","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.yrtph.2023.105438_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2022.105189","article-title":"Development of COVID-19 therapies: nonclinical testing considerations","volume":"132","author":"Baldrick","year":"2022","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"8","key":"10.1016\/j.yrtph.2023.105438_bib3","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.2105\/AJPH.2007.124537","article-title":"Adverse event detection in drug development: recommendations and obligations beyond phase 3","volume":"98","author":"Berlin","year":"2008","journal-title":"Am. J. Publ. Health"},{"issue":"6","key":"10.1016\/j.yrtph.2023.105438_bib4","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00204-020-02787-2","article-title":"Harnessing the power of novel animal-free test methods for the development of COVID-19 drugs and vaccines","volume":"94","author":"Busquet","year":"2020","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.yrtph.2023.105438_bib5","series-title":"Guideline on Repeated Dose Toxicity","article-title":"Committee for human medicinal products","year":"2010"},{"issue":"1","key":"10.1016\/j.yrtph.2023.105438_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/10915818221138781","article-title":"Nonclinical safety assessment of lipid nanoparticle-and emulsion-based self-amplifying mRNA vaccines in rats","volume":"42","author":"Donahue","year":"2023","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.yrtph.2023.105438_bib8","unstructured":"European Medicines Agency. Guideline on Data Requirements for Vaccine Platform Technology Master Files. Eur Med Agency. Published online 2022."},{"issue":"R2","key":"10.1016\/j.yrtph.2023.105438_bib11","first-page":"31","article-title":"ICH M3 (R2) - non-clinical Safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals","volume":"3","year":"2009","journal-title":"ICH Guidel"},{"key":"10.1016\/j.yrtph.2023.105438_bib12","volume":"vol. 5","year":"2020"},{"issue":"1","key":"10.1016\/j.yrtph.2023.105438_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/1471-0528.16973","article-title":"COVID-19 and novel mRNA vaccines in pregnancy: an updated literature review","volume":"129","author":"Joubert","year":"2022","journal-title":"BJOG An Int. J. Obstet. Gynaecol."},{"key":"10.1016\/j.yrtph.2023.105438_bib14","doi-asserted-by":"crossref","unstructured":"Kalafat E, Heath P, Prasad S, O'Brien P, Khalil A. COVID-19 vaccination in pregnancy. Am. J. Obstet. Gynecol.. Published online May 2022. doi:10.1016\/J.AJOG.2022.05.020.","DOI":"10.1016\/j.ajog.2022.05.020"},{"issue":"7830","key":"10.1016\/j.yrtph.2023.105438_bib15","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.yrtph.2023.105438_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/22221751.2020.1868951","article-title":"Susceptibility of rabbits to SARS-CoV-2","volume":"10","author":"Mykytyn","year":"2021","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.yrtph.2023.105438_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2021.105029","article-title":"Species selection for nonclinical safety assessment of drug candidates: examples of current industry practice","volume":"126","author":"Namdari","year":"2021","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"2 February","key":"10.1016\/j.yrtph.2023.105438_bib18","article-title":"mRNA Covid-19 vaccines in pregnancy: a systematic review","volume":"17","author":"Pratama","year":"2022","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.yrtph.2023.105438_bib19","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/01926233221090518","article-title":"Toxicity and local tolerance of a novel spike protein RBD vaccine against SARS-CoV-2, produced using the C1 thermothelomyces heterothallica protein expression platform","volume":"50","author":"Ramot","year":"2022","journal-title":"Toxicol. Pathol."},{"issue":"3","key":"10.1016\/j.yrtph.2023.105438_bib20","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/AOG.0000000000004290","article-title":"Coronavirus disease 2019 (COVID-19) vaccines and pregnancy: what obstetricians need to know","volume":"137","author":"Rasmussen","year":"2021","journal-title":"Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.yrtph.2023.105438_bib21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0300985817738095","article-title":"Safety evaluation of lipid nanoparticle-formulated modified mRNA in the sprague-dawley rat and cynomolgus monkey","volume":"55","author":"Sedic","year":"2018","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.yrtph.2023.105438_bib22","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3389\/fcimb.2021.735394","article-title":"COVID-19 vaccination in pregnancy and lactation: current research and gaps in understanding","volume":"11","author":"Shook","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.yrtph.2023.105438_bib23","series-title":"ATLAS.ti: the Qualitative Data Analysis","author":"ti GmbH","year":"2022"},{"key":"10.1016\/j.yrtph.2023.105438_bib24","article-title":"Considerations for developmental therapeutic vaccines for infectious toxicity studies for preventive and disease indications","year":"2006","journal-title":"Guidance for Industry"},{"issue":"1","key":"10.1016\/j.yrtph.2023.105438_bib25","first-page":"97","article-title":"Nonclinical testing of vaccines: report from a workshop","volume":"43","author":"Van Der Laan","year":"2009","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.yrtph.2023.105438_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.biologicals.2021.04.005","article-title":"IABS\/CEPI platform technology webinar: is it possible to reduce the vaccine development time?","author":"Vandeputte","year":"2021","journal-title":"Biologicals"},{"key":"10.1016\/j.yrtph.2023.105438_bib27","article-title":"COVID-19 vaccines","volume":"28","author":"Verbeke","year":"2022","journal-title":"Drugs Lact Database"},{"issue":"51","key":"10.1016\/j.yrtph.2023.105438_bib28","doi-asserted-by":"crossref","first-page":"7357","DOI":"10.1016\/j.vaccine.2021.10.048","article-title":"Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12-13 February 2020","volume":"39","author":"Voss","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.yrtph.2023.105438_bib29","author":"Wilson"},{"issue":"927","key":"10.1016\/j.yrtph.2023.105438_bib30","article-title":"WHO guidelines on nonclinical evaluation of vaccines","volume":"927","author":"World Health Organization","year":"2005","journal-title":"WHO Tech Rep Ser No"},{"key":"10.1016\/j.yrtph.2023.105438_bib31","series-title":"Guidelines on the Nonclinical Evaluation of Vaccine Adjuvants and Adjuvanted Vaccines","year":"2013"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027323002300106X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027323002300106X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:37:03Z","timestamp":1759495023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027323002300106X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":28,"alternative-id":["S027323002300106X"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2023.105438","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of non-clinical toxicity studies of COVID-19 vaccines","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2023.105438","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105438"}}